Skip to content

Clinical research for effective index and treating measure of latent tuberculosis

Clinical research for effective index and treating measure of latent tuberculosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16009727
Enrollment
Unknown
Registered
2016-11-03
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

latent tuberculosis

Interventions

negative control group:without any anti-tuberculosis drugs
isoniazid group:oral take isoniazid for 6 months
isoniazid + rifampicin + pyrazinamide + ethambutol group :isoniazid + rifampicin + pyoral take razinamide + ethambutol for 2 months
isoniazid+rifampicin group:oral take isoniazid+ rifampicin for 4 months
isoniazid+rifampicin+pyrazinamide group:isoniazid+rifampicin+pyrazinamide for 2 months

Sponsors

Respiratory Department, Fuling Central Hospital, Fuling District, Chongqing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The population has long-term contact with patients of active tuberculosis for one year or longer, including medical staff, family members of patients or population with low autoimmunity (such as diabetes or pneumonoconiosis patients); 2. Aged 20-70 years; 3. Diagnosis criteria of latent tuberculosis: PPD showed strong positive (+++) or T-SPOT showed positive (+).

Exclusion criteria

Exclusion criteria: 1. patients who diagnosed or suspected with active tuberculosis, including with following-up criteria: image show tuberculosis characteristic changes such as nodosity or fabric like shadows; relevant evidence of acid-fast bacillus were found in sputum or other body fluid species. 2. patients with obvious abnormal function of liver or kidney; patients have obvious disorder of coagulation; 3. Patients have disorder of vision or audition; 4. Grade 3-4 cardiac function, serious hypertension (blood pressure was still higher than 160/100mmHg after effective decompaction treatment), serious cardiac arrhythmias, aortic aneurysm, epilepsy or hypertension intracranial; 5. Patients with history of active tuberculosis; 6. refuse to anticipate this clinical research.

Design outcomes

Primary

MeasureTime frame
Rate of active tuberculosis;

Secondary

MeasureTime frame
Rate of adverse effect;

Countries

China

Contacts

Public ContactLisa Kuang

Fuling Central Hospital, Chongqing

kuanglisa926@163.com+86 15023313881

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026